Abstract Number: 939 • 2019 ACR/ARP Annual Meeting
A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obinutuzumab or Placebo in Combination with Mycophenolate Mofetil in Patients with Active Class III or IV Lupus Nephritis
Background/Purpose: Randomized trials in lupus nephritis (LN) of type I anti-CD20 monoclonal antibodies failed to demonstrate superiority over standard of care alone. NOBILITY (NCT02550652) is…Abstract Number: 2647 • 2018 ACR/ARHP Annual Meeting
Comparison of Low-Dose Intravenous Cyclophosphamide with Oral Mycophenolate Mofetil in the Treatment of Lupus Nephritis: Long Term Follow-up Data
Background/Purpose: We present the long-term follow-up of patients with lupus nephritis who completed the randomized controlled trial on comparison of low-dose intravenous cyclophosphamide (IV CYC)…Abstract Number: 766 • 2016 ACR/ARHP Annual Meeting
Withdrawal of Mycophenolate Mofetil after Maintenance Treatment of SLE Nephritis Associated with Renal Relapse
Background/Purpose: Current ACR and EULAR evidence based guidelines provide recommendations for therapeutic choices to induce and maintain remission of lupus nephritis, however, the appropriate duration…Abstract Number: 2941 • 2015 ACR/ARHP Annual Meeting
Outcomes in Lupus Nephritis Patients Previously Randomized to Receive Either Low Dose Cyclophosphamide Versus Oral Mycophenolate Mofetil on Azathioprine Maintenance
Background/Purpose: Management of SLE and lupus nephritis is challenging as it is always a trade off between remission, prevention of relapse and long term adverse…Abstract Number: 958 • 2014 ACR/ARHP Annual Meeting
The 10-Year Followup of a Trial Comparing Azathioprine and Mycophenolate Mofetil for Long-term Immunosuppression of Lupus Nephritis
Background/Purpose Very longterm data are rarely reported in lupus nephritis (LN) trials, despite their pivotal importance to detect late poor renal outcomers and to identify…
ACR Meeting Abstracts